This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Velcade
- Generic Name
- Bortezomib D-mannitol
- DrugBank Accession Number
- DB16741
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Bortezomib D-mannitol (DB16741)
- Weight
- Average: 530.39
Monoisotopic: 530.254794 - Chemical Formula
- C25H35BN4O8
- Synonyms
- Bortezomib D-mannitol ester
- Bortezomib D-mannitol symmetrical ester
- Bortezomib mannitol boronic ester
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Bortezomib D-mannitol is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Bortezomib D-mannitol is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Bortezomib D-mannitol is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Bortezomib D-mannitol is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Bortezomib D-mannitol is combined with Bupivacaine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Bortezomib prodrug 69G8BD63PP 179324-69-7 GXJABQQUPOEUTA-RDJZCZTQSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Act Bortezomib Powder, for solution 3.5 mg / vial Intravenous; Subcutaneous TEVA Canada Limited 2015-11-17 Not applicable Canada 
Bortezomib Powder, for solution 3.5 mg / vial Intravenous; Subcutaneous Apotex Corporation 2019-03-25 Not applicable Canada Bortezomib for Injection Powder, for solution 3.5 mg / vial Intravenous; Subcutaneous TEVA Canada Limited 2015-01-06 Not applicable Canada Bortezomib for Injection Powder, for solution 1 mg / vial Intravenous Juno Pharmaceuticals Corp. Not applicable Not applicable Canada Bortezomib for Injection Powder, for solution 1 mg / vial Intravenous; Subcutaneous Pfizer Canada Ulc Not applicable Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image PMS-bortezomib Powder, for solution 3.5 mg / vial Intravenous; Subcutaneous Pharmascience Inc 2018-06-05 Not applicable Canada Taro-bortezomib Powder, for solution 3.5 mg / vial Intravenous; Subcutaneous Taro Pharmaceuticals, Inc. 2021-04-12 Not applicable Canada Taro-bortezomib Powder, for solution 1 mg / vial Intravenous; Subcutaneous Taro Pharmaceuticals, Inc. Not applicable Not applicable Canada Taro-bortezomib Powder, for solution 2.5 mg / vial Intravenous; Subcutaneous Taro Pharmaceuticals, Inc. 2022-07-18 Not applicable Canada
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P2AWN9VSQ6
- CAS number
- 444576-08-3
- InChI Key
- QDMRNLRJDHCHLB-DNNBANOASA-N
- InChI
- InChI=1S/C25H35BN4O8/c1-15(2)10-21(26-37-22(19(33)13-31)23(38-26)20(34)14-32)30-24(35)17(11-16-6-4-3-5-7-16)29-25(36)18-12-27-8-9-28-18/h3-9,12,15,17,19-23,31-34H,10-11,13-14H2,1-2H3,(H,29,36)(H,30,35)/t17-,19+,20+,21-,22+,23+/m0/s1
- IUPAC Name
- (2S)-N-[(1R)-1-[(4R,5R)-4,5-bis[(1R)-1,2-dihydroxyethyl]-1,3,2-dioxaborolan-2-yl]-3-methylbutyl]-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamide
- SMILES
- [H][C@@]1(OB(O[C@]1([H])[C@H](O)CO)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=NC=CN=C1)[C@H](O)CO
References
- General References
- Not Available
- External Links
- ChemSpider
- 64854571
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Prevention Kidney Transplantation 1 4 Completed Treatment HLA Sensitization 1 4 Recruiting Treatment Multiple Myeloma (MM) 1 4 Terminated Treatment Multiple Myeloma (MM) 1 4 Unknown Status Treatment Multiple Myeloma (MM) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder, for solution Intravenous 1 mg / vial Powder, for solution Intravenous; Subcutaneous 1 mg / vial Powder, for solution Intravenous; Subcutaneous 2.5 mg / vial Powder, for solution Intravenous; Subcutaneous 3 mg / vial Powder, for solution Intravenous; Subcutaneous 3.5 mg / vial - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.639 mg/mL ALOGPS logP -0.21 ALOGPS logP 0.12 Chemaxon logS -2.9 ALOGPS pKa (Strongest Acidic) 12.75 Chemaxon pKa (Strongest Basic) -0.59 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 10 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 183.36 Å2 Chemaxon Rotatable Bond Count 13 Chemaxon Refractivity 130.22 m3·mol-1 Chemaxon Polarizability 55.93 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at November 27, 2021 17:13 / Updated at February 20, 2024 23:54